SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ISTA Analysis & Videos »
ISTA: Bull or Bear?
ISTA Pharmaceuticals Reports Second Quarter 2009 Financial Results and Raises Full Year Revenue Guidance
ISTA
|
|
|
-14.29%
in
93 days
<font> <font> Wednesday, August 05, 2009 4:00:00 PM ET </font> <> ISTA Pharmaceuticals, Inc. ( ISTA ), today reported financial results for the three months ended June 30, 2009. ISTA reported net revenue of $24.0 million for the three months ended June 30, 2009, a 35% increase over the same period of 2008. ISTA’s operating loss for the second quarter ended June 30, 2009 was $1.6 million or a 79% reduction from $7.8 million for the same period in 2008. As a result of the strong quarter, ISTA raised its guidance range for full year 2009 revenue to between $95 and $100 million. IS<><><>< />< />< />< />< />< />< />< />< />< />< />< />< />< />< /><><><><><><><><><>< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< /><><><><><><><><><><>< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< /><><><><>< />...
|
Target Price Raised
ISTA
|
|
|
-5.05%
in
131 days
<> <> NEW YORK, June 29 (newratings.com) - Analysts at RBC Capital Markets maintain their "sector perform" rating on ISTA Pharmaceuticals (ISTA) . The target price has been raised from $3 to $5.
In a research note published this morning, the analysts mention that an FDA panel has voted 7-0 in favour of approving Bepreve. The FDA approval reduces some risk related to the approval of Bepreve, the analysts say. ISTA Pharmaceuticals is likely to launch the drug by in January 2010, RBC Capital Markets adds. The company’s share price has, ho...
|
FDA Extreme Trades: 16 Stocks Under $5
ISTA
|
|
|
-7.89%
in
133 days
<> Below are FDA extreme trades among 16 companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> (database includes 225 entries as of 6/27/09) which have pending FDA decisions for either new drug products, biological agents, medical devices, or diagnostic tests that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <> <font> Extreme FDA and Clinical Trial Calendar Trade...
|
Bullish on ISTA ...
ISTA
|
|
|
+92.86%
in
181 days
ISTA Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye in the United States. The company offers Xibrom for the treatment of inflammation and pain following cataract surgery; Istalol for the treatment of glaucoma; and Vitrase for use as a spreading agent. Its developing products include Bepotastine ophthalmic solution for allergic conjunctivitis; T-Pred, a Phase III clinical trial product candidate for the treatment of steroid-responsive inflammatory ocular conditions; Ecabet S...
|
People Bullish on ISTA
People Bearish on ISTA
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ISTA |
Be the first to start a discussion and earn 2 points.
More Resources
|
About ISTA Pharmaceuticals Inc.
- Answers.com
